Home › Companies › NEUROCRINE BIOSCIENCES INC. › 2024-2025
Compiled from SEC Form N-PX filings and NEUROCRINE BIOSCIENCES INC.’s Form 8-K, filed May 22, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of May 21, 2025: 6 items on NEUROCRINE BIOSCIENCES INC.’s Form 8-K, filed May 22, 2025: 4 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore NEUROCRINE BIOSCIENCES INC. in the interactive database Compare manager voting policies
These tallies are NEUROCRINE BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 22, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Kyle W. Gano, Ph.D. | 84,346,100 | -- | -- | 1,382,673 | 4,705,420 | 98% | Elected | — |
| Elect Director: Richard F. Pops | 72,919,088 | -- | -- | 12,809,685 | 4,705,420 | 85% | Elected | — |
| Elect Director: Shalini Sharp | 79,466,551 | -- | -- | 6,262,222 | 4,705,420 | 93% | Elected | — |
| Elect Director: Stephen A. Sherwin, M.D. | 79,505,052 | -- | -- | 6,223,721 | 4,705,420 | 93% | Elected | — |
| The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the 2025 Plan. | 72,648,862 | 12,884,104 | 195,807 | -- | 4,705,420 | 85% | Approved | — |
| The 2025 Plan was approved. • Approval of the Amended and Restated ESPP. | 85,402,588 | 138,042 | 188,143 | -- | 4,705,420 | 99.8% | Approved | — |
Source: NEUROCRINE BIOSCIENCES INC., Form 8-K, filed with the SEC on May 22, 2025 — read the filing on EDGAR.
Each item below shows how the 575 asset managers that disclosed a NEUROCRINE BIOSCIENCES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NEUROCRINE BIOSCIENCES INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 9 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Kyle W. Gano, Ph.D.
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Kyle W. Gano, Ph.D.”): 84,346,100 for, 1,382,673 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The four nominees for Class II Director were elected.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 140 asset managers below reported 40,996,649 for, 79,309 withheld, 39,551 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,700,124 | 0 | 0 | 0 | For |
| BlackRock | 7,784,392 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,444,463 | 0 | 0 | 0 | For |
| State Street | 1,958,694 | 0 | 0 | 121 | For |
| Fidelity | 1,848,674 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,123,708 | 0 | 0 | 0 | For |
| Thrivent | 864,157 | 0 | 0 | 0 | For |
| JPMorgan | 860,703 | 0 | 0 | 0 | For |
| Charles Schwab | 762,890 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 605,452 | 0 | 0 | 0 | For |
| First Trust | 589,586 | 0 | 0 | 0 | For |
| Prudential/PGIM | 577,726 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 428,399 | 0 | 0 | 0 | For |
| Goldman Sachs | 357,823 | 0 | 0 | 0 | For |
| Invesco | 352,119 | 0 | 0 | 0 | For |
| Dimensional | 349,976 | 0 | 0 | 0 | For |
| TIAA | 305,938 | 0 | 0 | 0 | For |
| Allspring | 303,305 | 0 | 0 | 0 | For |
| Jackson National | 297,757 | 0 | 0 | 0 | For |
| Equitable | 274,819 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 254,720 | 0 | 0 | 0 | For |
| John Hancock | 246,261 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 240,176 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 222,414 | 0 | 0 | 0 | For |
| Aberdeen | 219,912 | 0 | 0 | 0 | For |
Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.
Combines 8 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Richard F. Pops
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Richard F. Pops”): 72,919,088 for, 12,809,685 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The four nominees for Class II Director were elected.”
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 139 asset managers below reported 37,047,232 for, 3,789,872 withheld, 253,205 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,700,123 | 0 | 1 | 0 | For |
| BlackRock | 7,784,392 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,444,463 | 0 | 0 | 0 | For |
| State Street | 5,851 | 0 | 0 | 1,952,964 | Withhold |
| Fidelity | 1,848,674 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 1,123,708 | Withhold |
| Thrivent | 864,157 | 0 | 0 | 0 | For |
| JPMorgan | 860,703 | 0 | 0 | 0 | For |
| Charles Schwab | 762,890 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 605,452 | 0 | 0 | 0 | For |
| First Trust | 589,586 | 0 | 0 | 0 | For |
| Prudential/PGIM | 577,726 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 428,399 | 0 | 0 | 0 | For |
| Goldman Sachs | 357,823 | 0 | 0 | 0 | For |
| Invesco | 352,119 | 0 | 0 | 0 | For |
| Dimensional | 349,976 | 0 | 0 | 0 | For |
| TIAA | 305,938 | 0 | 0 | 0 | For |
| Allspring | 303,305 | 0 | 0 | 0 | For |
| Jackson National | 116,130 | 0 | 181,627 | 0 | Mixed |
| Equitable | 67,346 | 0 | 0 | 207,473 | Mixed |
| Manager Directed Portfolios | 254,720 | 0 | 0 | 0 | For |
| John Hancock | 229,602 | 0 | 16,659 | 0 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 240,176 | Withhold |
| Brown Advisory Funds | 222,414 | 0 | 0 | 0 | For |
| Aberdeen | 219,912 | 0 | 0 | 0 | For |
Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.
Combines 8 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Shalini Sharp
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Shalini Sharp”): 79,466,551 for, 6,262,222 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The four nominees for Class II Director were elected.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 139 asset managers below reported 39,341,783 for, 1,717,234 withheld, 31,292 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,700,123 | 0 | 1 | 0 | For |
| BlackRock | 7,784,392 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,444,463 | 0 | 0 | 0 | For |
| State Street | 1,958,815 | 0 | 0 | 0 | For |
| Fidelity | 1,848,674 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 1,123,708 | Withhold |
| Thrivent | 864,157 | 0 | 0 | 0 | For |
| JPMorgan | 860,703 | 0 | 0 | 0 | For |
| Charles Schwab | 762,890 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 605,452 | 0 | 0 | 0 | For |
| First Trust | 589,586 | 0 | 0 | 0 | For |
| Prudential/PGIM | 577,726 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 428,399 | 0 | 0 | 0 | For |
| Goldman Sachs | 357,823 | 0 | 0 | 0 | For |
| Invesco | 352,119 | 0 | 0 | 0 | For |
| Dimensional | 349,976 | 0 | 0 | 0 | For |
| TIAA | 305,938 | 0 | 0 | 0 | For |
| Allspring | 303,305 | 0 | 0 | 0 | For |
| Jackson National | 297,757 | 0 | 0 | 0 | For |
| Equitable | 67,346 | 0 | 0 | 207,473 | Mixed |
| Manager Directed Portfolios | 254,720 | 0 | 0 | 0 | For |
| John Hancock | 229,602 | 0 | 16,659 | 0 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 240,176 | Withhold |
| Brown Advisory Funds | 222,414 | 0 | 0 | 0 | For |
| Aberdeen | 219,912 | 0 | 0 | 0 | For |
Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.
Combines 9 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Stephen A. Sherwin, M.D.
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Stephen A. Sherwin, M.D.”): 79,505,052 for, 6,223,721 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The four nominees for Class II Director were elected.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 139 asset managers below reported 39,301,233 for, 1,718,233 withheld, 70,843 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,700,123 | 0 | 1 | 0 | For |
| BlackRock | 7,784,392 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,444,463 | 0 | 0 | 0 | For |
| State Street | 1,958,694 | 0 | 0 | 121 | For |
| Fidelity | 1,848,674 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 1,123,708 | Withhold |
| Thrivent | 864,157 | 0 | 0 | 0 | For |
| JPMorgan | 860,703 | 0 | 0 | 0 | For |
| Charles Schwab | 762,890 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 605,452 | 0 | 0 | 0 | For |
| First Trust | 589,586 | 0 | 0 | 0 | For |
| Prudential/PGIM | 577,726 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 428,399 | 0 | 0 | 0 | For |
| Goldman Sachs | 357,823 | 0 | 0 | 0 | For |
| Invesco | 352,119 | 0 | 0 | 0 | For |
| Dimensional | 349,976 | 0 | 0 | 0 | For |
| TIAA | 305,938 | 0 | 0 | 0 | For |
| Allspring | 303,305 | 0 | 0 | 0 | For |
| Jackson National | 297,757 | 0 | 0 | 0 | For |
| Equitable | 67,346 | 0 | 0 | 207,473 | Mixed |
| Manager Directed Portfolios | 254,720 | 0 | 0 | 0 | For |
| John Hancock | 229,602 | 0 | 16,659 | 0 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 240,176 | Withhold |
| Brown Advisory Funds | 222,414 | 0 | 0 | 0 | For |
| Aberdeen | 219,912 | 0 | 0 | 0 | For |
Showing the 25 largest of 139 asset managers. See all 139 in the interactive database.
Combines 5 wordings of this item as funds reported it.
92% of fund votes cast · no official result
The 140 asset managers below reported 37,726,180 for, 3,311,217 against, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,699,890 | 234 | 0 | 0 | For |
| BlackRock | 7,784,392 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,444,463 | 0 | 0 | 0 | For |
| State Street | 5,851 | 1,952,964 | 0 | 0 | Against |
| Fidelity | 1,679,954 | 168,720 | 0 | 0 | Mixed |
| T. Rowe Price | 1,123,708 | 0 | 0 | 0 | For |
| Thrivent | 864,157 | 0 | 0 | 0 | For |
| JPMorgan | 860,703 | 0 | 0 | 0 | For |
| Charles Schwab | 762,890 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 605,452 | 0 | 0 | 0 | For |
| First Trust | 589,586 | 0 | 0 | 0 | For |
| Prudential/PGIM | 68,470 | 509,256 | 0 | 0 | Mixed |
| JANUS INVESTMENT FUND | 428,399 | 0 | 0 | 0 | For |
| Goldman Sachs | 357,823 | 0 | 0 | 0 | For |
| Invesco | 352,119 | 0 | 0 | 0 | For |
| Dimensional | 349,976 | 0 | 0 | 0 | For |
| TIAA | 305,938 | 0 | 0 | 0 | For |
| Allspring | 303,305 | 0 | 0 | 0 | For |
| Jackson National | 297,757 | 0 | 0 | 0 | For |
| Equitable | 274,819 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 254,720 | 0 | 0 | 0 | For |
| John Hancock | 246,261 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 240,176 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 222,414 | 0 | 0 | 0 | For |
| Aberdeen | 219,912 | 0 | 0 | 0 | For |
Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: To approve an amendment and restatement of the Company's 2018 Employee Stock Purchase Plan; and
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The 2025 Plan was approved. • Approval of the Amended and Restated ESPP.”): 85,402,588 for, 138,042 against — passed, per its Form 8-K filed May 22, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The 2025 Plan was approved.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of NEUROCRINE BIOSCIENCES INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Employee Stock Purchase Plan” (2 managers, 23,334 for).
The 85 asset managers below reported 26,891,117 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,187,585 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,444,463 | 0 | 0 | 0 | For |
| State Street | 1,958,815 | 0 | 0 | 0 | For |
| Fidelity | 1,848,674 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,123,708 | 0 | 0 | 0 | For |
| Thrivent | 864,157 | 0 | 0 | 0 | For |
| First Trust | 589,586 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 428,399 | 0 | 0 | 0 | For |
| Goldman Sachs | 357,823 | 0 | 0 | 0 | For |
| Invesco | 352,119 | 0 | 0 | 0 | For |
| Dimensional | 349,976 | 0 | 0 | 0 | For |
| TIAA | 305,938 | 0 | 0 | 0 | For |
| Allspring | 303,305 | 0 | 0 | 0 | For |
| Equitable | 274,819 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 240,176 | 0 | 0 | 0 | For |
| Aberdeen | 219,912 | 0 | 0 | 0 | For |
| Lincoln Financial | 198,799 | 0 | 0 | 0 | For |
| Eaton Vance | 196,747 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 166,630 | 0 | 0 | 0 | For |
| Principal | 153,501 | 0 | 0 | 0 | For |
| Voya | 144,241 | 0 | 0 | 0 | For |
| American Century | 143,889 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 137,205 | 0 | 0 | 0 | For |
| MFS | 132,581 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 126,124 | 0 | 0 | 0 | For |
Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.
99.8% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2018 EMPLOYEE STOCK PURCHASE PLAN.
NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The 2025 Plan was approved. • Approval of the Amended and Restated ESPP.”): 85,402,588 for, 138,042 against — passed, per its Form 8-K filed May 22, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The 2025 Plan was approved.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 61 asset managers below reported 14,134,733 for, 52,716 against, 0 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 7,784,392 | 0 | 0 | 0 | For |
| Vanguard | 1,512,539 | 0 | 0 | 0 | For |
| JPMorgan | 860,703 | 0 | 0 | 0 | For |
| Charles Schwab | 762,890 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 605,452 | 0 | 0 | 0 | For |
| Prudential/PGIM | 508,826 | 430 | 0 | 0 | For |
| Jackson National | 297,757 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 254,720 | 0 | 0 | 0 | For |
| John Hancock | 246,261 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 222,414 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 153,801 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 100,000 | 0 | 0 | 0 | For |
| Hartford | 95,391 | 0 | 0 | 0 | For |
| AMG FUNDS | 90,658 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 73,079 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 72,062 | 0 | 0 | 0 | For |
| SEI | 65,082 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 63,110 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 52,286 | 0 | 0 | Against |
| Integral Health Asset Management, LLC | 43,023 | 0 | 0 | 0 | For |
| Six Circles Trust | 39,723 | 0 | 0 | 0 | For |
| Mercer Funds | 39,092 | 0 | 0 | 0 | For |
| Baird | 36,349 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 25,200 | 0 | 0 | 0 | For |
| Russell Investments | 23,615 | 0 | 0 | 0 | For |
Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.
Combines 9 wordings of this item as funds reported it.
95% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,699,228 | 896 | 0 | 0 | For |
| BlackRock | 7,784,392 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,444,463 | 0 | 0 | 0 | For |
| State Street | 1,958,815 | 0 | 0 | 0 | For |
| Fidelity | 1,848,674 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,123,708 | 0 | 0 | 0 | For |
| Thrivent | 864,157 | 0 | 0 | 0 | For |
| JPMorgan | 860,703 | 0 | 0 | 0 | For |
| Charles Schwab | 762,890 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 605,452 | 0 | 0 | 0 | For |
| First Trust | 589,586 | 0 | 0 | 0 | For |
| Prudential/PGIM | 577,726 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 428,399 | 0 | 0 | 0 | For |
| Goldman Sachs | 357,823 | 0 | 0 | 0 | For |
| Invesco | 0 | 352,119 | 0 | 0 | Against |
| Dimensional | 349,976 | 0 | 0 | 0 | For |
| TIAA | 305,938 | 0 | 0 | 0 | For |
| Allspring | 303,305 | 0 | 0 | 0 | For |
| Jackson National | 297,757 | 0 | 0 | 0 | For |
| Equitable | 274,819 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 254,720 | 0 | 0 | 0 | For |
| John Hancock | 246,261 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 240,176 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 222,414 | 0 | 0 | 0 | For |
| Aberdeen | 219,912 | 0 | 0 | 0 | For |
Fund voting reports, all 137 managers: 40,447,426 for, 541,500 against, 2 withheld, 52,286 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 5,667,431 | 0 | 0 | 0 | For |
| Dodge & Cox | 5,271,050 | 0 | 0 | 0 | For |
| State Street | 4,608,520 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,928,824 | 0 | 0 | 0 | For |
| Wellington | 1,688,043 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,541,479 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1,398,693 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 0 | 1,167,298 | 0 | Abstain |
| Renaissance | 1,078,404 | 0 | 0 | 0 | For |
| Thrivent | 878,815 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 876,620 | 0 | 0 | 0 | For |
| Charles Schwab | 818,798 | 0 | 0 | 0 | For |
| Northern Trust | 788,698 | 0 | 0 | 0 | For |
| Janus Henderson | 760,216 | 0 | 0 | 0 | For |
| BROWN ADVISORY INC | 751,330 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 742,939 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 733,419 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 727,471 | 0 | 0 | 0 | For |
| UBS | 632 | 671,946 | 0 | 0 | Against |
| BRAIDWELL LP | 623,378 | 0 | 0 | 0 | For |
| AQR | 563,961 | 0 | 0 | 0 | For |
| EAGLE ASSET MANAGEMENT INC | 550,054 | 0 | 0 | 0 | For |
| AllianceBernstein | 528,627 | 0 | 0 | 0 | For |
| Invesco | 0 | 484,994 | 0 | 0 | Against |
| GW&K Investment Management, LLC | 476,244 | 0 | 0 | 0 | For |
Institutional-manager reports, all 464 managers: 46,761,829 for, 4,301,808 against, 1,201,269 abstained, 2,700 not voted. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% of fund votes cast · no official result
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
The 137 asset managers below reported 40,951,335 for, 30,485 against, 52,286 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,699,228 | 896 | 0 | 0 | For |
| BlackRock | 7,784,392 | 0 | 0 | 0 | For |
| Dodge & Cox | 4,444,463 | 0 | 0 | 0 | For |
| State Street | 1,958,694 | 121 | 0 | 0 | For |
| Fidelity | 1,848,674 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,123,708 | 0 | 0 | 0 | For |
| Thrivent | 864,157 | 0 | 0 | 0 | For |
| JPMorgan | 860,703 | 0 | 0 | 0 | For |
| Charles Schwab | 762,890 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 605,452 | 0 | 0 | 0 | For |
| First Trust | 589,586 | 0 | 0 | 0 | For |
| Prudential/PGIM | 577,726 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 428,399 | 0 | 0 | 0 | For |
| Goldman Sachs | 357,823 | 0 | 0 | 0 | For |
| Invesco | 352,119 | 0 | 0 | 0 | For |
| Dimensional | 349,976 | 0 | 0 | 0 | For |
| TIAA | 305,938 | 0 | 0 | 0 | For |
| Allspring | 303,305 | 0 | 0 | 0 | For |
| Jackson National | 297,757 | 0 | 0 | 0 | For |
| Equitable | 274,819 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 254,720 | 0 | 0 | 0 | For |
| John Hancock | 246,261 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 240,176 | 0 | 0 | 0 | For |
| Brown Advisory Funds | 222,414 | 0 | 0 | 0 | For |
| Aberdeen | 219,912 | 0 | 0 | 0 | For |
Showing the 25 largest of 137 asset managers. See all 137 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 99,000,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.82% |
| 2 | BlackRock | 7.86% |
| 3 | Dodge & Cox | 4.49% |
| 4 | State Street | 1.98% |
| 5 | Fidelity | 1.87% |
| 6 | T. Rowe Price | 1.14% |
| 7 | Thrivent | 0.87% |
| 8 | JPMorgan | 0.87% |
| 9 | Charles Schwab | 0.77% |
| 10 | CARILLON SERIES TRUST | 0.61% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 5.72% |
| 2 | Dodge & Cox | 5.32% |
| 3 | State Street | 4.66% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 1.95% |
| 5 | Wellington | 1.71% |
| 6 | T. Rowe Price | 1.56% |
| 7 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1.41% |
| 8 | BNP Paribas Asset Management Holding S.A. | 1.18% |
| 9 | Renaissance | 1.09% |
| 10 | Thrivent | 0.89% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 14.83% | 13F |
| The Vanguard Group | 10.23% | DEF14A |
| Dodge & Cox | 5.59% | 13G |
| State Street | 4.91% | 13F |
| JPMorgan Chase | 2.70% | 13F |
| Renaissance Technologies | 2.53% | 13F |
| Wellington Management | 2.12% | 13F |
| Kevin C. Gorman, Ph.D. | 1.57% | DEF14A |
| T. Rowe Price | 1.56% | 13F |
| Morgan Stanley | 1.53% | 13F |
Percentages above are of 99,000,000 shares outstanding, as reported by NEUROCRINE BIOSCIENCES INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NEUROCRINE BIOSCIENCES INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At NEUROCRINE BIOSCIENCES INC.'s shareholder meeting held May 21, 2025, in the 2024-2025 proxy season, 575 asset managers reported how they voted in their SEC Form N-PX filings, covering 5,789 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. NEUROCRINE BIOSCIENCES INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Advisory vote on the compensation paid to the Company's named executive officers. — the reporting funds and managers cast 95% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
NEUROCRINE BIOSCIENCES INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.